Type 1 Diabetes Mellitis
10
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Impact of Integrated Pet Care on Glycemic Control and Diabetes Responsibility
Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)
Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise
Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State
Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
Metabolic Control and Glycemic Variability in Type 1 Diabetes and Celiac Disease
Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes
Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)